Seeking Alpha
19 Nov 2026, 23:41 UTC · 1h ago
Novo Nordisk: A Return To Growth May Be Just Around The Corner
Impact · against what's priced in
The article is largely noise for Eli Lilly as the competitive pressure from Novo Nordisk's pipeline is already a known bear-case risk. For Novo Nordisk, the potential for CagriSema to close the efficacy gap with Lilly represents a catalyst for valuation recovery, though current 2026 guidance beats are likely already reflected in the price.
- LLY−0.10
Already priced in
- The price assumes
The bear case that GLP-1 concentration risk and competitive pressure from Novo Nordisk's oral Wegovy will compress margins
The mention of Novo Nordisk's oral Wegovy and CagriSema as tools to close the efficacy gap reinforces the competitive pressure the market is already weighing as a risk to Lilly's dominance.
What LLY's price assumes · Sep 10

Search tags




